Friday, 16 Aug 2019

You are here

Rituximab Superior to Cyclosporine for Membranous Nephropathy

The NEJM has reported that rituximab (RTX) and cyclosporine (CYA) was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. 

The study enrolled 130 patients with membranous nephropathy, proteinuria of > 5 g per 24 hours, and a creatinine clearance of > 40 ml per minute per 1.73 m2 of body-surface area.  Patients were on background ACE inhibitors and were randomized to receive at least 3 months of intravenous rituximab (two infusions, 1000 mg each, administered 14 days apart; repeated at 6 months in case of partial response) or oral cyclosporine (starting at a dose of 3.5 mg per kilogram of body weight per day for 12 months). The primary outcome was a composite of complete or partial remission of proteinuria at 24 months.

The results at 12 months showed a complete or partial remission:

  • RTX = 60%
  • CyA = 52%

These results were compatible with noninferiority (risk difference, 8 percentage points; 95% confidence interval [CI], −9 to 25; P=0.004 for noninferiority).

The rate of complete or partial remission at 24 months:

  • RTX = 60%
  • CyA = 20%

in the cyclosporine group had a complete or partial remission (risk difference, 40 percentage points; 95% CI, 25 to 55; P<0.001 for both noninferiority and superiority).

Among patients in remission who tested positive for anti–phospholipase A2 receptor (PLA2R) antibodies, the decline in autoantibodies to anti-PLA2R was faster and of greater magnitude and duration in the rituximab group than in the cyclosporine group.

There was a trend towards fewer serious adverse events with RTX (17%) compared to CyA (31%) (P=0.06).

Membranous glomerulonephritis appears to respond well to B-cell depletion with rituximab as it is noninferior to cyclosporine for inducing complete or partial remission of proteinuria over 12 mos but is superior ovr 24 mos and has fewer adverse effects. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Vitamin D Supplements Fail to Prevent Type 2 Diabetes - DUH!

A NEJM report shows that the use of vitamin D3 supplementation (4000 IU per day) in those without diabetes or vitamin D deficiency failed to significantly lower risk of type 2 diabetes (compared to placebo).

The rational for this report included observational data showing an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes.

Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants

The comparative risk for gastrointestinal bleeding (GIB) with non-vitamin K antagonist oral anticoagulants (NOACs) was compared to vitamin K antagonists or anti-platelet agents in a recent metanalysis, which showed no significant difference in major GIB events between these agents.

Management of Hemophagocytic Lymphohistiocytosis (HLH) in Adults

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome induced by activated macrophages and cytotoxic T cells.  HLH manifests recurrent fever, cytopenia, liver dysfunction, and a sepsis-like syndrome that may complicated by multiple organ failure.

More Trouble for Mallinckrodt’s Acthar Gel

Reuters has reported that Mallinckrodt Plc has tentatively agreed to pay $15.4 million to resolve a US Justice Department investigation into company promotional practices for Acthar gel.

FDA Public Review of CBD Oil

The US Food and Drug Administration convened a public hearing and specialty panel on May 31st to review the potential use, safety and effectiveness of cannabidiol (CBD) products that do not contain THC.

In his opening remarks, the FDA acting Commissioner Dr. Ned Sharpless said, "critical questions remain about the safety" of CBD products, especially since the growth of the CBD market has exploded in the past year.